ATXN7 Antibody is a laboratory reagent used to detect ataxin-7, a core component of the SAGA chromatin remodeling complex. Its primary applications include immunoprecipitation, immunofluorescence microscopy, and Western blotting to study protein localization, interactions, and post-translational modifications (PTMs). These antibodies target epitopes in the full-length protein or specific domains, such as the N-terminal polyglutamine (polyQ) tract or regions involved in microtubule binding .
ATXN7 Antibody is employed in multiple experimental contexts to elucidate its physiological and pathological roles:
Used to isolate ATXN7 and its interacting partners:
Key Findings:
ATXN7 interacts with α-tubulin via residues 120–230, stabilizing microtubules .
PolyQ-expanded ATXN7 retains interaction with SAGA complex subunits (e.g., Trrap, Gcn5) but disrupts histone deubiquitination .
Caspase 7 cleavage sites in ATXN7 release the deubiquitination module (DUBm) from SAGA, impairing transcriptional regulation .
Visualizes subcellular localization and aggregation:
Key Findings:
Assesses protein stability and PTMs:
Key Findings:
ATXN7 binds α-tubulin, stabilizing cytoskeletal structures. PolyQ expansion does not disrupt this interaction but reduces cytoplasmic ATXN7 levels, leading to microtubule instability .
Nuclear Inclusions: PolyQ ATXN7 aggregates in nuclei, impairing transcriptional regulation and causing photoreceptor degeneration .
Chromatin Dysregulation: Mutant ATXN7 alters histone modifications (e.g., H2B monoubiquitination) and disrupts recruitment of SAGA complexes to target genes .
TFTC/STAGA Complex: PolyQ ATXN7 does not reduce histone acetyltransferase (HAT) activity but disrupts chromatin organization, leading to misregulated gene expression .
Mitochondrial Dysfunction: ATXN7 acetylation and aggregation correlate with impaired oxidative phosphorylation and mitochondrial fragmentation .